Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Arexvy in Immunocompromised Patients
NCT06597916Phase 2Recruiting
- Sponsor
- Medical University of Vienna
- Start
- Sep 2024
- Primary completion
- Aug 2025
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of GSK3003899A in respiratory syncytial virus infection (RSV), sponsored by Medical University of Vienna. Started Sep 2024; status: recruiting.
02
Drugs
GSK3003899A
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT06597916.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06597916.